Winning Stock Forecast: OMI Gains 63.51% in 3 Days

source: Wikimedia

Over the period of August 7th to August 10th, OMI stock (Owens & Minor Inc., NASDAQ: OMI) price rose by 63.51% following a strong buy rating given by I Know First’s market forecasting algorithm.

OMI Business Overview

Owens & Minor, Inc. (OMI), together with its subsidiaries, operates as a healthcare logistics company. It operates through two segments, Domestic and International. The company offers supply chain assistance to the providers of healthcare services; and the manufacturers of healthcare products, supplies, and devices. Its service portfolio consists of procurement, inventory management, delivery

Read More

Winning Stock Forecast: DAN And VAC Returns Up to 30.59% and 22.96% in 14 Days.

Dana Incorporated (NYSE: DAN)

[Image Source: commons.wikimedia.org]
Dana Incorporated announced preliminary 2018 financial results and guidance for 2019. Growth of 13% in sales and 15% in adjusted EBITDA, compared with 2017, due to strong end-market demand, conversion of sales backlog and acquisition synergies. The completion of the acquisition of the Drive Systems Segment of the Oerlikon Group (ODS), expected to close by the end of February of 2019 and the acquisition of SME Group is a good reason to stay long. The company’s electrified product portfolio will expand and will be strengthened by Drive System of Oerlikon group, enabling DAN to provide products for a broad range of hybrid and electric-vehicle configurations.

DAN expectations for 2019 are to increase their sales in the range of 1.4% to 5.0%, including ODS they expect growth in sales in the range of 10.0% to 14.9%. Regarding the adjusted EBITDA they expect growth of 3.9% to 10.2%, and including ODS the growth would be in the range of 13.4% to 21.7%. Based on the expectations for this year, the acquisition of ODS could increase their results significantly.

 

Marriott Vacations Worldwide Corporation (NYSE: VAC)

[Image Source: wikipedia.org]
In the Hotels sector Marriott Vacations Worldwide (VAC) is becoming an attractive stock. In the past quarters the earnings where according to the estimations, so it’s becoming more predictable. For the next quarter there is a wide range in the estimations, but the bearish sentiment is very low.

P/B ratio for VAC is 1.17, so the stock’s market value is similar to the book value, therefore is a well valuated stock with positive expectations among the investors.

The chart below shows the algorithmic forecast made on these stocks one month ago and the results of the forecast. As seen DAN and VAC where both included in the top ten stocks.

Current I Know First subscribers received these bullish forecasts for DAN and VAC on 4th of January, 2019.

 To subscribe today click here.

 Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster.

How to interpret this diagram

About

Dana Incorporated, formerly Dana Holding Corporation, incorporated on December 7, 2007, is a global provider of technology driveline, sealing and thermal-management products. The Company offers its products to vehicle manufacturers in the global light vehicle, medium/heavy vehicle and off-highway markets. The Company operates in four segments: Light Vehicle Driveline Technologies (Light Vehicle), Commercial Vehicle Driveline Technologies (Commercial Vehicle), Off-Highway Driveline Technologies (Off-Highway) and Power Technologies. It has operations in North America, South America, Europe and Asia pacific.

Marriott Vacations Worldwide Corporation, incorporated on June 21, 2011, focuses entirely on vacation ownership, based on number of owners, number of resorts and revenues. The Company is a worldwide developer, marketer, seller and manager of vacation ownership and related products under the Marriott Vacation Club and Grand Residences by Marriott brands. The Company operates through three segments, including North America, Europe and Asia Pacific. In the North America segment, it develops, markets, sells and manages vacation ownership and related products under the Marriott Vacation Club and Grand Residences by Marriott brands. It also develops, markets and sells vacation ownership and related products under The Ritz-Carlton Destination Club brand, as well as whole ownership residential products under The Ritz-Carlton Residences brand. Its Europe segment is engaged in selling its existing projects and managing existing resorts. Its Asia Pacific segment, it develops, markets, sells and manages two points-based programs that it designed to appeal to the vacation preferences of the market, Marriott Vacation Club, Asia Pacific and Marriott Vacation Club Destinations, Australia, as well as a weeks-based right-to-use product. Its business focuses on selling vacation ownership products; managing its resorts; financing consumer purchases of vacation ownership products, and renting vacation ownership inventory.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

Disclaimer

Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.

Winning WLK Stock Forecast: Westlake Chemical Partners Returns 22.53% in 14 Days

 

[Image Source: businesswire.com]
Westlake has seen a sharp rise of its stock in the recent few weeks, as it has received growing attention from investors and traders. As of Q3 2018 Robotti Robert has 5.73% invested in the company. Another 55,056 shares of Westlake Chemical Partners are owned by Contradictory Investment Management. Many more institutional clients hold large sums of stocks. WLK pays a dividend of 7.19%, which is very high compared to the industry average. It pays out 97.7% of its earning to its stockholders. On February 19 WLK is expected to report its quarterly earnings. Analysts expect earnings per share of $0.38, which is $0.08 down to prior year. The main reason for the latest rise in the stock, is that the stock declined over the last few months and many investors regarded this a good chance to buy stocks.

WLK saw a rise of 22.53% over a period of 14 days. The stock rose mainly due to the low valuation of the company. The stock rose constantly during the beginning of the 14-day period.

The chart below shows the forecast of I Know First and the top 10 stock picks published on December 25, I Know First has issued 14 days bullish forecast for WLK with the signal of 2.29 and the predictability of 0.48.

Current I Know First subscribers received this bullish forecast for WLK on December 25th.

To subscribe today click here.

How to interpret this diagram

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster.

About

Westlake Chemical Corporation, incorporated on September 3, 1991, is a global manufacturer and marketer of basic chemicals, vinyls, polymers and building products. The Company’s products include a range of chemicals, which are fundamental to various consumer and industrial markets, including flexible and rigid packaging, automotive products, coatings, water treatment, refrigerants, residential and commercial construction, as well as other durable and non-durable goods. The Company operates in two segments: Olefins and Vinyls. The Company is also an integrated producer of vinyls with substantial downstream integration into polyvinyl chloride (PVC) building products.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

Disclaimer

Before making any trading decisions, consult the latest forecast as the algorithm updates predictions daily. You can use the algorithm for intra-day trading. The predictability tends to become stronger with forecasts over longer time-horizons such as the 1-month, 3-month and 1-year forecasts.

Winning Stock Forecast: NUGT And VXX Returns Up to 15.95% and 14.43%

Winning Stock Forecast: NUGT And VXX Performers In ETF Package

 

On December 20th, 2018, I Know First’s top stock predicting algorithm conducted it’s 7-Day World ETFs Package Forecast.

The full ETFs Package includes a daily forecast for a total of 20 ETFs with bullish and bearish signals. This package contains top 10 picks for the long, and top 10 picks for the short position, which are determined by screening our database daily using our advanced algorithm and selecting those with the highest predictability and signal.

In our winning stock forecast, we have the two most noteworthy performers of this particular forecast: VXX and NUGT both for the long position.

The package itself, had an overall average return of 4.94%, in the long position, providing a premium of 5.66% over the SP500’s return of -0.72%. With regards to the short position, the package had an overall average performance of 2.11%, providing investors with a premium of 2.83% over S&P500’s return of -0.72%.

I Know First's Outlook

Winning Stock Forecast: Arrowhead Pharmaceuticals (NASDAQ: ARWR) Returns up to 321.18% in 1 Year

Source https://it.depositphotos.com/3798928/stock-photo-tablets-medicines.html

Since the beginning of 2018 Arrowhead Pharmaceuticals showed growth catalysts for this year. First, according to the quarterly report for the period ended December 31, 2017, on September 28, 2016 the Company entered into a collaboration agreement with Amgen Inc. The Company received a worldwide license for ARO-AMG1, an RNAi therapy for an undisclosed genetically validated cardiovascular target, that makes Amgen wholly responsible for clinical development and commercialization of this technology. Moreover, the Company has sold 3,002,793 common stocks to Amgen at a price of $7.16 each. This agreement seems to be still fruitful.

The Company entered into the license agreement with Janssen Pharmaceuticals, Inc. (part of the Janssen Pharmaceuticals Companies of Johnson & Johnson) for ARO-HBV and collaboration for up to three RNAi therapeutic candidates that use TRiM TM platform. The total deal value is approximately $3.7 billion. Additionally, on January 18, 2018 Arrowhead announced the pricing of an underwritten public offering of 10 million  shares of its common stock at a price of $5.25 per share, before underwriting discounts. Net proceeds to the Company were approximately $56.7 million after deducting underwriting commissions and discounts and other offering expenses payable by the Company. This IPO gave undoubtedly a strong boost to the company’s finances. At the end of 2017, Arrowhead declared $11.5 million in cash, and $39.2 million in short-term investments.

 

I Know First’s Outlook

Best Stocks Under 5

ARWR stock is one of the most predictable assets by I Know First’s AI algorithm and the above annual prediction provided an impressive result – the return totaled to 321.18%. Arrowhead stock was already mentioned in our previous winning stock forecast for different investment horizons, for instance our 3 months Winning stock forecast based on this bullish prediction by I Know First AI algorithm. In accordance with the our 1 year prediction for ARWR the stock price followed the below path:

Algorithmic traders utilize daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster.

To learn how you can become a subscriber today, click here.

Please note-for trading decisions use the most recent forecast.

The Company

Arrowhead Pharmaceuticals (NASDAQ: ARWR) develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company’s preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company’s pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-HBV is designed to silence the production of all hepatitis B virus (HBV) gene products. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency (AATD). ARO-AAT is designed to knock down the Alpha-1 antitrypsin (AAT) gene transcript and reduce the hepatic production of the mutant AAT protein.

Winning Stock Forecast: Biopharma Company Amarin Corporation PLC (NASDAQ: AMRN) Brings 16.01 % In 7 Days

AMRN Winning Stock Forecast

Source: kisspng.com

This week biopharma company AMRN saw a 16.01 % jump, being the 7 day forecast’s biggest earner, as the I Know First algorithm predicted. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid. Heart Disease is still the leading factor for deaths in the USA and following recent patient trials Vascepa users are 25% less likely to suffer from a cardiac arrest. These impressive results thrust Vascepa as the industry leader drug for those suffering with high cholesterol.

Amarin Corporation lost $92 million this year because sales of Vascepa just haven’t kept pace with operating expenses. However, they are putting huge investment into turning their drug Vascepa into a ‘blockbuster.’ Many critics are often sceptical about such investment but in this case it appears that Amarin may be an exception. With a positive trail the market reaction has seen Amarin as a company with long term potential and investors will continue to support this drug.

Source: maxpixel.net

Current I Know First subscribers received a bullish AMRN forecast on October 11th. With a strong signal of 31.89 for the week-long time frame.

Traders and investors utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers on October 11th.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

About

Amarin Corporation plc, incorporated on March 1, 1989, is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers

Winning AMD Stock Forecast (NASDAQ: AMD): Chip Maker AMD Continues To Surge The Market

Winning AMD Stock Forecast

 AMD’s Ryzen Close Up.  By Fritzchens Fritz from Berlin (via WikiMediaCommons/Public Domain)

Advanced Micro Devices Inc. (AMD) went from a company that was once in fair amount of trouble, to a competitor against giants Nvidia and Intel. Shares have been seeing a continuous rise, reaching a 12-year high. The stock rose 200% this past month alone. AMD’s Ryzen microprocessors can take a fair amount of credit for this success. That along with quality leadership with Lisa Su as CEO. Ryzen outperforms competitor Intel’s comparable chips, and at a lower price. The same outperformance can be seen for EPYC against the likes of Intel’s Xeon, and notably so. Since AMD’s launch of EPYC processors last year, they have gradually gained share within the server market space. They are also set to launch next-generation 7 nanometer products soon, well ahead of their competitors which aren’t scheduled to drop until 2020. This gives AMD a window to take a hold of even more market share in the coming year. Their avoidance of certain security issues that have hit competitors in recent moths may have been yet another factor in their recent uprise. Ryzen and EPYC, which brought this company back to life, are getting a ramp, which should be a good sign to shareholders. The company is optimistic about a 20% share in the desktop market, up to 40% in 2019, driven by Ryzen chips. It is also notable that AMD’s market is growing, and this means though it may have healthy competitors, their presentation of solid product may be gaining them a more solidified position in the market. They supply rapidly growing markets like smartphones, data-centers, AI, AR/VR, self-driving, automation, etc. The total addressable market (TAM) took a massive jump from $18.5 billion to $22.5 billion, which only helps a company like AMD grow, as long as they keep delivering great product.

AMD saw an impressive second quarter, with a revenue of $1.76 billion, a 53% rise year-over-year. It also reported its highest quarterly net income in seven years. Earnings per Share (EPS) increased by 700% from the previous-year quarter, and 50% from Q1 2018.

On September 18, Mizuho increases its AMD (NASDAQ:AMD) price target from $20 to $36

On the next day, Morgan Stanley reiterates an Underweight rating on AMD (NASDAQ:AMD) but increases the price target from $11 to $28

On September 20, Stifel increases its AMD (NASDAQ:AMD) price target from $21 to $38 citing strong demand for the company’s new products

Two day ago Jefferies reiterates its Buy rating and raises its AMD (NASDAQ:AMD) price target from $30 to $36.

I Know First was one of the first to give AMD a bullish outlook via our stock forecasting algorithm. On June 10 we publish this bullish outlook for AMD detailing 3 driving forces for this bullish outlook

AMD is up 97% since this bullish forecast

(Source: Yahoo Finance)

A week before these mulitply upgradings we issued this bullish short term forecast for AMD:

 

 

AMD is with 19% gain since this bullish short term forecast

 

(Source: Yahoo Finance)

Current I Know First subscribers received this bullish AMD forecast on September 9th, 2018.

To subscribe today click here.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance

Read More

Winning Stock Forecast: OPK Returns 30.46% in 7 Days, Fueled by Future Drug Expectations

“Scientific advancement should aim to affirm and to improve human life.”

– Nathan Deal

(Source: Cleveland Clinic)

OPKO Health, Inc. (NASDAQ: OPK) is a diversified healthcare company. Incorporated on November 18, 1991, the company’s segments include pharmaceutical, diagnostics, and corporate. The company’s pharmaceutical operations

Read More

Pages:12»